Orient Technologies (NSE: ORIENTTECH) Q3 FY26 results: Why short-term margin pain may be the price of securing long-cycle government and services revenue
Read More 6 minute read Pharma Industry News FDA Complete Response Letter puts Disc Medicine Inc.’s bitopertin timeline under pressure Disc Medicine Inc. shares plunge after the FDA issues a Complete Response Letter for bitopertin. Find out what this setback means for investors and strategy. byPallavi MadhirajuFebruary 14, 2026